Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells
Introduction
Acute myeloid leukaemia (AML) is a heterogenous malignant disease with diverse biological features in which disease progression at the level of CD34+ cells has a major impact on resistance to chemotherapy and relapse [1]. Approximately 60% of the AML cases are in patients older than 60 years [2]. These elderly patients do not respond well to the current conventional chemotherapy used in younger AML patients due to the intrinsic resistant nature of their AML cells and/or their poor tolerance to the conventional chemotherapy regimens [3]. Very little progress has been made over the past 30 years in the treatment outcome of the AML patients older than 60 years and using chemotherapy.
The AML blast cells in these elderly patients are often characterised by several unfavourable covariates that predict poor treatment outcome, including high stem cell marker CD34 expression, minimally or undifferentiated features, high P-glycoprotein expression, high bcl-2/bax ratio, unfavourable karyotype and more frequent internal tandem duplications (ITDs) and mutations of the class III receptor-type tyrosine kinase for key haematopoietic cytokines: Flt-3 (receptor for Flt-ligand), c-kit (receptor for stem cell factor) and fms (receptor for M-CSF) [4], [5], [6], [7], [8], [9], [10], [11], [12], [13]. The frequent occurrence of ITDs and mutations in this receptor tyrosine kinase for Flt-3, c-kit and fms in AML cells were reported in 25–35%, 10–20% and 5–20% of the elderly patients, respectively [14]. Several tyrosine kinase inhibitors have been recently synthesised including imatinib (Gleevec or ST1571) as c-kit inhibitor, CEP-701 as flt-3 inhibitor and SU5416 as inhibitor for all the three, flt-3, c-kit and fms [14]. Their pilot phase I/II clinical trials as single agents in refractory AML patients revealed modest clinical activity in these patients and tolerable side-effects [15], [16], [17], [18], [19], [20].
Testing the new and more specific molecular targeted therapeutic approaches in CD34+ AML cells can provide the basis for a more effective combined molecular/chemotherapy regimen and may consequently improve the treatment outcome in elderly AML patients.
The stem cell factor (SCF) receptor: c-kit is expressed in 63% of the AML patients, two-third of which are also CD34+ and have lower complete remission rate and poor prognosis [21], [22]. Both c-kit and CD34 are overexpressed in AML blast cells compared to normal bone marrow [23] and associated with significant low complete remission and relapse-free survival rates among the AML patients [24], [25]. Also, c-kit exon 8 mutations seem to be a significant factor adversely affecting the relapse rate [26].
On the other hand, there is little information about the effect of the antibody against SCF (anti-SCF) on the chemotherapy cytotoxicity in AML cells. Therefore, the present study was performed to evaluate whether anti-SCF can enhance the efficacy of the two main chemotherapeutic drugs used in AML therapy: cytarabine and daunorubicin at low doses in human-resistant CD34+ AML cells in an attempt to identify a novel effective regimen with tolerable side-effects for elderly AML patients. The effect of anti-SCF on each of the two chemotherapeutic drugs-induced apoptosis and necrosis was investigated in KG1a human-resistant CD34+ AML cells expressing P-glycoprotein to determine its enhancing activity.
Section snippets
Human CD34+ resistant myeloid leukaemia cells
The human CD34+ myeloid leukaemia cell line: KG1a (European Collection of Cell Cultures, Salisbury, UK) were grown in RPMI-1640 culture medium (Sigma–Aldrich, UK) supplemented with 10% foetal bovine serum (Sigma–Aldrich, UK) at 37 °C in a humidified 5% CO2 incubator. Cell count and viability were assessed every 3 days using Coulter® EPICS® XL™ Flow Cytometer (Beckman Coulter™, UK). The cell viability was maintained at >97% and the doubling time for KG1a cells is about 50 h.
Treatment of human CD34+ resistant myeloid leukaemia cells
KG1a cells cultured in
Results
In the control cultures, there was only minimal spontaneous apoptosis and necrosis of only 2.5 and 2.0%, respectively, in KG1a CD34+ AML cells. In SCF-treated cultures, the total number of viable KG1a CD34+ AML cells increased to between 105.6 and 129.5% of the control cultures, whereas in anti-SCF-treated cultures, the total number of viable KG1a CD34+ cells decreased to between 66.6 and 95.3% of the control cultures. The spontaneous apoptosis + necrosis in SCF- and anti-SCF-treated KG1a CD34+
Discussion
Since their introduction in the 1960s and 1970s, cytarabine and daunorubicin have been the standard chemotherapy for the induction and consolidation of remission in AML patients. The combined use of cytarabine and daunorubicin for induction followed by high dose cytarabine for consolidation led to the achievement of up to 80% complete remission with 5-year survival of approximately 40% in younger adult AML patients [30]. Unfortunately, the disappointing outlook for the older AML patients has
References (39)
- et al.
Acute myeloid leukaemia in the older patient
Crit Rev Oncol Hematol
(2003) - et al.
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukaemia (AML): analysis of 1065 patients entered into tyjyhe UK MRC AMasL11 trial
Blood
(2001) - et al.
Frequency and clinical significance of the expression of the multi-drug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukaemiaA Southwest Oncology Group study
Blood
(1999) - et al.
FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukaemia
Blood
(2001) - et al.
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukaemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
Blood
(2002) - et al.
Analysis of FLt2-activating mutations in 979 patients with acute myelogenous leukaemia: association with FAB subtypes and identification of subgroups with poor prognosis
Blood
(2002) - et al.
Molecular targets in acute myelogenous leukaemia
Blood Rev
(2003) - et al.
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory secondary AML
Blood
(2003) - et al.
Efficacy and safety of imatinib in adult patients with c-kit-positive AML
Blood
(2004) - et al.
A phase 2 clinical study of SU5416 in patients with refractory AML
Blood
(2003)
Effect of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukaemia
Leuk Res
CD34 and Cd117 are over-expressed in AML and may be valuable to detect minimal residual disease
Leuk Res
Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukaemia
Leuk Res
Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down regulation of bcl-2 in human myeloid leukaemia CD34 positive cells
Leuk Res
The therapy of relapsed acute leukaemia in adults
Blood Rev
Phase III study of the MDR modulator: PSC-883 in previously untreated patients 60 years of age and older with AML: cancer and leukaemia group B study 9720
Blood
Phase I and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukaemia
Blood
CD34 positive cell sorting and enrichment: applications in blood banking and transplantation
Acute myeloid leukaemia in the elderly
Blood Rev
Cited by (16)
Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment
2016, Cancer LettersCitation Excerpt :Over the years anti-SCF agents have not been developed even if it has been demonstrated that SCF expression is correlated to poor outcome in some malignancies [128–130]. In this regard, one experimental study showed the ability of human SCF-Ab to enhance cytarabine and daunorubicin cytotoxicity in human-resistant CD34 + AML cells [131]. Gabexate mesylate (GM-Foy®) is a synthetic inhibitor of trypsin-like serine proteases [71] with an antiproteinase activity on plasma proteases, including thrombin, plasmin, trypsin, kallikrein, C1 esterase in the complement system, and factor Xa in the coagulation cascade.
Crystal structure of streptavidin mutant with low immunogenicity
2015, Journal of Bioscience and BioengineeringSelective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin
2020, BMC Complementary Medicine and TherapiesStem cell factor antibody: Effective manipulation of antihormonal therapy in resistant human breast cancer in vitro
2019, International Journal of Drug Delivery TechnologyThe Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response
2017, BMC Complementary and Alternative Medicine